(Q35276315)

7 August 2017

title

Comparative in vitro activity of a new quinolone, fleroxacin, against respiratory pathogens from patients with cystic fibrosis (English)

1 reference

7 August 2017

0 references

0 references

J C Akaniro

1

1 reference

7 August 2017

C E Vidaurre

series ordinal

2

1 reference

7 August 2017

H R Stutman

series ordinal

3

1 reference

7 August 2017

M I Marks

series ordinal

4

1 reference

7 August 2017

language of work or name

English

0 references

publication date

1 October 1990

1 reference

Antimicrobial Agents and Chemotherapy

7 August 2017

published in

1 reference

7 August 2017

volume

34

1 reference

7 August 2017

issue

10

1 reference

7 August 2017

page(s)

1880-1884

1 reference

DNA Gyrase and the Supercoiling of DNA

7 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=171958

Ciprofloxacin versus tobramycin plus azlocillin in pulmonary exacerbations in adult patients with cystic fibrosis

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=171958

Improved medium for antimicrobial susceptibility testing of Haemophilus influenzae

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=171958

In vitro susceptibility of Pseudomonas aeruginosa from bacteremic and fibrocystic patients to four quinolones and five other antipseudomonal antibiotics.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=171958

Fleroxacin: in-vitro activity worldwide against 20,807 clinical isolates and comparison to ciprofloxacin and norfloxacin.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=171958

In-vitro activity of fleroxacin compared with three other quinolones

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=171958

Development of resistance in Pseudomonas aeruginosa to imipenem, norfloxacin, and ciprofloxacin during therapy: proof provided by typing with a DNA probe

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=171958

Single- and multiple-dose pharmacokinetics of fleroxacin, a trifluorinated quinolone, in humans

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=171958

The post-antimicrobial suppressive effect of quinolone agents.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=171958

Pharmacokinetics and tissue penetration of Ro 23-6240, a new trifluoroquinolone

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=171958

In vitro activity of Ro 23-6240, a new difluoroquinolone derivative, compared with that of other antimicrobial agents

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=171958

In vitro activity of Ro 23-6240, a new fluorinated 4-quinolone

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=171958

Inhibition of Micrococcus luteus DNA gyrase by norfloxacin and 10 other quinolone carboxylic acids

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=171958

Oral ciprofloxacin compared with conventional intravenous treatment for Pseudomonas aeruginosa infection in adults with cystic fibrosis

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=171958

In-vitro and in-vivo antibacterial activity of fleroxacin, a new fluorinated quinolone.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=171958

In vitro activity of E-1040, a 3-substituted cephalosporin, against pathogens from cystic fibrosis sputum

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=171958

Mucoid strains of Pseudomonas aeruginosa: the influence of culture medium on the stability of mucus production

27 July 2018

1 reference

12 December 2020

Ciprofloxacin for eradication of methicillin-resistant Staphylococcus aureus colonization

1 reference

12 December 2020

Postantibiotic suppression of bacterial growth

1 reference

12 December 2020

In-vitro activity of ciprofloxacin and other antibacterial agents against Pseudomonas aeruginosa and Pseudomonas cepacia from cystic fibrosis patients

1 reference

12 December 2020

Post-antibiotic effect of ciprofloxacin on Pseudomonas aeruginosa

1 reference

12 December 2020

Effect of method, medium, pH and inoculum on the in-vitro antibacterial activities of fleroxacin and norfloxacin

1 reference

12 December 2020

Fluoroquinolone antimicrobial agents

1 reference

12 December 2020

Persistent effect of antibiotics on Staphylococcus aureus after exposure for limited periods of time

1 reference

12 December 2020

Identifiers

DOI

10.1128/AAC.34.10.1880

1 reference

7 August 2017

1 reference

7 August 2017

1 reference